Medical Oncology

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


972 publications

... | 2019 | 2018 | 2017 | 2016 | ...
2019
Sex Hormones and Anticancer Immunity.
Özdemir B.C., Dotto G.P., 2019/08/01. Clinical cancer research, 25 (15) pp. 4603-4610. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2A2BB09AAB25]
 
The RANK-RANKL axis: an opportunity for drug repurposing in cancer?
Peters S., Clézardin P., Márquez-Rodas I., Niepel D., Gedye C., 2019/08. Clinical & translational oncology, 21 (8) pp. 977-991. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_70A2BC9FF3FA]
 
Implementation of the Symptom Navi © Programme for cancer patients in the Swiss outpatient setting: a study protocol for a cluster randomised pilot study (Symptom Navi© Pilot Study).
Bana M., Ribi K., Kropf-Staub S., Zürcher-Florin S., Näf E., Manser T., Bütikofer L., Rintelen F., Peters S., Eicher M., 2019/07/09. BMJ open, 9 (7) pp. e027942. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B3F3DE9F9737]
Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immune checkpoint inhibitors for first- or second-line treatment of advanced gastric and gastro-esophageal junction cancer
Özdemir Berna C, Moehler Markus, Syn Nicholas LX, Tai Bee-Choo, Wagner Anna Dorothea, 2019/07/03. Cochrane Database of Systematic Reviews.
[URN][DOI][serval:BIB_EE24E14551F4]
 
A Systematic Review and Meta-analysis of the Combination of Vinorelbine and Lapatinib in Patients With Her2-positive Metastatic Breast Cancer.
Stravodimou A., Voutsadakis I.A., 2019/07. Anticancer research, 39 (7) pp. 3295-3301. Peer-reviewed.
[DOI][Pmid][serval:BIB_798BD609E807]
Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network.
Darlix A., Mandonnet E., Freyschlag C.F., Pinggera D., Forster M.T., Voss M., Steinbach J., Loughrey C., Goodden J., Banna G. et al., 2019/07. Neuro-oncology practice, 6 (4) pp. 264-273. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_075881197C02]
 
Human epidermal growth factor receptor 2-positive digestive tumors.
Wagner A.D., Özdemir B.C., Rüschoff J., 2019/07. Current opinion in oncology, 31 (4) pp. 354-361. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_79ED6368F476]
 
MedCo: Enabling Secure and Privacy-Preserving Exploration of Distributed Clinical and Genomic Data
Raisaro Jean Louis, Troncoso-Pastoriza Juan Ramon, Misbach Mickael, Sousa Joao Sa, Pradervand Sylvain, Missiaglia Edoardo, Michielin Olivier, Ford Bryan, Hubaux Jean-Pierre, 2019/07/01. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 16 (4) pp. 1328-1341. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EB26A9E809D5]
 
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
Peters S., Felip E., Dafni U., Belka C., Guckenberger M., Irigoyen A., Nadal E., Becker A., Vees H., Pless M. et al., 2019/07. Lung cancer, 133 pp. 83-87. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CDB53E596949]
 
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
Camidge D.R., Dziadziuszko R., Peters S., Mok T., Noe J., Nowicka M., Gadgeel S.M., Cheema P., Pavlakis N., de Marinis F. et al., 2019/07. Journal of thoracic oncology, 14 (7) pp. 1233-1243. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B6BC9B5EAA4E]
 
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).
Dziadziuszko R., Smit E.F., Dafni U., Wolf J., Wasąg B., Biernat W., Finn S.P., Kammler R., Tsourti Z., Rabaglio M. et al., 2019/06. Journal of thoracic oncology, 14 (6) pp. 1086-1094. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CF4397F632F3]
 
How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer.
Peters S., Reck M., Smit E.F., Mok T., Hellmann M.D., 2019/06/01. Annals of oncology, 30 (6) pp. 884-896. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EE544EB386BD]
 
Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy.
Perrinjaquet C., Desbaillets N., Hottinger A.F., 2019/06. Current opinion in neurology, 32 (3) pp. 500-510. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8503B3CB45D8]
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner A.D., Grabsch H.I., Mauer M., Marreaud S., Caballero C., Thuss-Patience P., Mueller L., Elme A., Moehler M.H., Martens U. et al., 2019/05/24. BMC cancer, 19 (1) p. 494. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7D31BF0D4734]
De sérieuses préoccupations qui ne cachent pas nos espoirs.
Aapro M., Peters S., Dietrich P.Y., 2019/05/15. Revue medicale suisse, 15 (651) pp. 999-1000. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_21A539F75FCF]
 
Nouvelles options thérapeutiques du cancer pulmonaire à l’ère de l’immunothérapie [The new management options for lung cancer in the immunotherapy era]
Meganem H., Socianu R.M., Bouchaab H., Mederos N., Nguyen-Ngoc T., Peters S., Dolcan A., 2019/05/15. Revue medicale suisse, 15 (651) pp. 1032-1037. Peer-reviewed.
[Pmid][serval:BIB_919816F771EB]
Nouvelles stratégies thérapeutiques dans les cancers mammaire et tubo-ovarien de stade avancé [New therapeutic strategies in advanced stage breast and tubo-ovarian cancers]
Nikolopoulou A., Galli-Vareia I., Stravodimou A., Sarivalasis A., Zaman K., 2019/05/15. Revue medicale suisse, 15 (651) pp. 1027-1031. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_44ECB7C03967]
 
Solid cancer development in solid organ transplant recipients within the Swiss Transplant Cohort Study.
Lengwiler E., Stampf S., Zippelius A., Salati E., Zaman K., Schäfer N., Schardt J., Siano M., Hofbauer G., The Swiss Transplant Cohort Study, 2019/05/06. Swiss medical weekly, 149 pp. w20078. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_45BD46BF05E6]
 
A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.
Kerr K.M., Thunnissen E., Dafni U., Finn S.P., Bubendorf L., Soltermann A., Verbeken E., Biernat W., Warth A., Marchetti A. et al., 2019/05. Lung cancer, 131 pp. 95-103. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C471070F0828]
 
Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer.
Martinez P., Peters S., Stammers T., Soria J.C., 2019/05/01. Clinical cancer research, 25 (9) pp. 2691-2698. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D1FB33C27208]
Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08).
Curioni-Fontecedro A., Perentes J.Y., Gelpke H., Xyrafas A., Bouchaab H., Mach N., Matzinger O., Stojcheva N., Frueh M., Weder W. et al., 2019/05. British journal of cancer, 120 (10) pp. 968-974. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6DA91E6BDAAE]
 
The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma.
Lutz M.P., Zalcberg J.R., Ducreux M., Adenis A., Allum W., Aust D., Carneiro F., Grabsch H.I., Laurent-Puig P., Lordick F. et al., 2019/05. European journal of cancer, 112 pp. 1-8. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5456782E7024]
 
Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma.
Gartrell R.D., Marks D.K., Rizk E.M., Bogardus M., Gérard C.L., Barker L.W., Fu Y., Esancy C.L., Li G., Ji J. et al., 2019/04/15. Clinical cancer research, 25 (8) pp. 2494-2502. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D7E13D945FBE]
Neoadjuvant chemoradiotherapy delivered with helical tomotherapy under daily image guidance for rectal cancer patients: efficacy and safety in a large, multi-institutional series.
De Bari B., Franzetti-Pellanda A., Saidi A., Biggiogero M., Hahnloser D., Montemurro M., Bourhis J., Zeverino M., Ozsahin M., 2019/04. Journal of cancer research and clinical oncology, 145 (4) pp. 1075-1084. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_89462433D524]
 
Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study.
Blackwell K.L., Zaman K., Qin S., Tkaczuk KHR, Campone M., Hunt D., Bryce R., Goldstein L.J., 202 Study Group, 2019/04. Clinical breast cancer, 19 (2) pp. 97-104.e4. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AF7D20CA1A7F]
 
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations.
Neuzillet C., Casadei Gardini A., Brieau B., Vivaldi C., Smolenschi C., Brandi G., Tougeron D., Filippi R., Vienot A., Silvestris N. et al., 2019/04. European journal of cancer, 111 pp. 94-106. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_22AA367A9AFD]
 
Systemic treatment in elderly head and neck cancer patients: recommendations for clinical practice.
Szturz P., Bossi P., Vermorken J.B., 2019/04. Current opinion in otolaryngology & head and neck surgery, 27 (2) pp. 142-150. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E76BF67C06EC]
Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre.
Jermini M., Dubois J., Rodondi P.Y., Zaman K., Buclin T., Csajka C., Orcurto A., Rothuizen L.E., 2019/03/25. Scientific reports, 9 (1) p. 5078. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EB0D132F2B63]
Circulating CD56<sup>bright</sup> NK cells inversely correlate with survival of melanoma patients.
de Jonge K., Ebering A., Nassiri S., Maby-El Hajjami H., Ouertatani-Sakouhi H., Baumgaertner P., Speiser D.E., 2019/03/14. Scientific reports, 9 (1) p. 4487. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_07410EEFFC5B]
 
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.
Lai W.V., Lebas L., Barnes T.A., Milia J., Ni A., Gautschi O., Peters S., Ferrara R., Plodkowski A.J., Kavanagh J. et al., 2019/03. European journal of cancer, 109 pp. 28-35. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F346FD4D55B1]
Intraductal patient-derived xenografts of estrogen receptor α-positive breast cancer recapitulate the histopathological spectrum and metastatic potential of human lesions.
Fiche M., Scabia V., Aouad P., Battista L., Treboux A., Stravodimou A., Zaman K., RLS, Dormoy V., Ayyanan A. et al., 2019/03. The Journal of pathology, 247 (3) pp. 287-292. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_86A544986D24]
 
Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis.
Necchi A., Mariani L., Lo Vullo S., Yu E.Y., Woods M.E., Wong Y.N., Harshman L.C., Alva A., Sternberg C.N., Bamias A. et al., 2019/03. European urology focus, 5 (2) pp. 242-249. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8DC541D54E75]
 
Reply to L. Pala et al.
Wagner A.D., Özdemir B., Csajka C., 2019/02/10. Journal of clinical oncology, 37 (5) pp. 439-440. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3B355EA54937]
50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
Herrera F.G., Valerio M., Berthold D., Tawadros T., Meuwly J.Y., Vallet V., Baumgartner P., Thierry A.C., De Bari B., Jichlinski P. et al., 2019/02/01. International journal of radiation oncology, biology, physics, 103 (2) pp. 320-334. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8A5A6B3310C5]
Inappropriate Grading of Adverse Events in Cancer Clinical Trials-Reply.
Cristina V., Mauer M., Wagner A.D., 2019/02/01. JAMA oncology, 5 (2) pp. 269-270. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D4F7397E30A8]
 
Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours-the MACBETH project.
Cazzaniga M.E., Ciruelos E., Fabi A., Garcia-Saenz J., Lindman H., Mavroudis D., Schem C., Steger G., Timotheadou E., Zaman K. et al., 2019/02. Cancer chemotherapy and pharmacology, 83 (2) pp. 301-318. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A309F7C661D2]
 
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS.
Wu Y.L., Planchard D., Lu S., Sun H., Yamamoto N., Kim D.W., Tan DSW, Yang J.C., Azrif M., Mitsudomi T. et al., 2019/02/01. Annals of oncology, 30 (2) pp. 171-210. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_889FD36DE7B3]
 
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
Peters S., Dafni U., Boyer M., De Ruysscher D., Faivre-Finn C., Felip E., Garrido P., Girard N., Guckenberger M., Haanen J. et al., 2019/02/01. Annals of oncology, 30 (2) pp. 161-165. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_996A49F24542]
Safety and Tolerability of Adoptive Cell Therapy in Cancer.
Wolf B., Zimmermann S., Arber C., Irving M., Trueb L., Coukos G., 2019/02. Drug safety, 42 (2) pp. 315-334. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_944ED4AF4291]
 
Brain metastases.
Achrol A.S., Rennert R.C., Anders C., Soffietti R., Ahluwalia M.S., Nayak L., Peters S., Arvold N.D., Harsh G.R., Steeg P.S. et al., 2019/01/17. Nature reviews. Disease primers, 5 (1) p. 5. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_74BE7AFBB48B]
 
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.
Ruhstaller T., Giobbie-Hurder A., Colleoni M., Jensen M.B., Ejlertsen B., de Azambuja E., Neven P., Láng I., Jakobsen E.H., Gladieff L. et al., 2019/01/10. Journal of clinical oncology, 37 (2) pp. 105-114. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D4E4E78E667C]
 
Oncologie [Oncology, what's new in 2018]
Latifyan S., Kakourou A., Ozdemir B., Zaman K., Vernadou A., Berthold D., Abdelhamid K., Bouchaab H., Peters S., Montemurro M. et al., 2019/01/09. Revue medicale suisse, 15 (N° 632-633) pp. 78-81. Peer-reviewed.
[Pmid][serval:BIB_E686DFA1B1CC]
A Novel Approach to Better Characterize Medication Adherence in Oral Anticancer Treatments.
Schneider M.P., Achtari Jeanneret L., Chevaux B., Backes C., Wagner A.D., Bugnon O., Luthi F., Locatelli I., 2019. Frontiers in Pharmacology, 9 p. 1567. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4C48EDB2AC56]
 
Characterisation of rare haematological immune-related toxicities.
Haanen J.B., Peters S., 2019/01. The Lancet. Haematology, 6 (1) pp. e10-e11. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3D5F42DE561C]
Cisplatin Eligibility Issues and Alternative Regimens in Locoregionally Advanced Head and Neck Cancer: Recommendations for Clinical Practice.
Szturz P., Cristina V., Herrera Gómez R.G., Bourhis J., Simon C., Vermorken J.B., 2019. Frontiers in oncology, 9 p. 464. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_76EEE8FBE7D2]
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
Chan T.A., Yarchoan M., Jaffee E., Swanton C., Quezada S.A., Stenzinger A., Peters S., 2019/01/01. Annals of oncology, 30 (1) pp. 44-56. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_352758F0496B]
Immunotherapy of Cancer: Developments and Reference Points, an Unorthodox Approach.
Nikolaou M., Nikolaou G., Digklia A., Pontas C., Tsoukalas N., Kyrgias G., Tolia M., 2019. Integrative cancer therapies, 18 p. 1534735419827090. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CA340C972534]
 
La médecine personnalisée en oncologie dans: Médecine Personnalisée
Colomer-Lahiguera S., Coukos G., Peters S., Kandalaft L., Michielin O., Eicher M., 2019. dans Médecine Personnalisée, Académie Suisse de Sciences Médicales.
[serval:BIB_B2FAEFC8A271]
 
Leptomeningeal tumor response to combined MAPK/ERK inhibition in V600E-mutated gliomas despite undetectable CSF drug levels.
Hottinger A.F., Bensaid D., De Micheli R., Moura B., Mokhtari K., Cardoso E., Idbaih A., Stupp R., 2019/01/01. Annals of oncology, 30 (1) pp. 155-156. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_54D10906FAA6]
Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer.
Szturz P., Wouters K., Kiyota N., Tahara M., Prabhash K., Noronha V., Adelstein D., Van Gestel D., Vermorken J.B., 2019. Frontiers in oncology, 9 p. 86. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_78A5B254D97C]
 
Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy.
Evrard D., Szturz P., Tijeras-Raballand A., Astorgues-Xerri L., Abitbol C., Paradis V., Raymond E., Albert S., Barry B., Faivre S., 2019/01. Oral oncology, 88 pp. 29-38. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3A5FCD94382F]
 
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01).
Früh M., Betticher D.C., Stupp R., Xyrafas A., Peters S., Ris H.B., Mirimanoff R.O., Ochsenbein A.F., Schmid R., Matzinger O. et al., 2019/01. Journal of thoracic oncology, 14 (1) pp. 115-123. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C7AD177ACA8A]
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.
Martins F., Sykiotis G.P., Maillard M., Fraga M., Ribi C., Kuntzer T., Michielin O., Peters S., Coukos G., Spertini F. et al., 2019/01. The Lancet. Oncology, 20 (1) pp. e54-e64. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_42DB9145A8A7]
Theranostics in Interventional Oncology: Versatile Carriers for Diagnosis and Targeted Image-Guided Minimally Invasive Procedures.
Degrauwe N., Hocquelet A., Digklia A., Schaefer N., Denys A., Duran R., 2019. Frontiers in pharmacology, 10 p. 450. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_871EAEDDCDA1]
 
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.
Peters S., Stahel R., Bubendorf L., Bonomi P., Villegas A., Kowalski D.M., Baik C.S., Isla D., Carpeno J.C., Garrido P. et al., 2019/01/01. Clinical cancer research, 25 (1) pp. 64-72. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9F5780E6B02C]
VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study.
Smyth E., Knödler M., Giraut A., Mauer M., Nilsson M., Van Grieken N., Wagner A.D., Moehler M., Lordick F., 2019. Frontiers in oncology, 9 p. 1320. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_3144C154E1E3]
2018
 
Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation.
Clocchiatti A., Ghosh S., Procopio M.G., Mazzeo L., Bordignon P., Ostano P., Goruppi S., Bottoni G., Katarkar A., Levesque M. et al., 2018/12/03. The Journal of clinical investigation, 128 (12) pp. 5531-5548. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DB6A4F3B1607]
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program.
Peters S., Curioni-Fontecedro A., Nechushtan H., Shih J.Y., Liao W.Y., Gautschi O., Spataro V., Unk M., Chih-Hsin Yang J., Lorence R.M. et al., 2018/12. Journal of thoracic oncology, 13 (12) pp. 1897-1905. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_29FF3A29D783]
Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort.
Rulle U., Tsourti Z., Casanova R., Deml K.F., Verbeken E., Thunnissen E., Warth A., Sejda A., Cheney R., Speel E.J. et al., 2018/12. Journal of thoracic oncology, 13 (12) pp. 1851-1863. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_73E30C0132C1]
 
Immune-modulating antibodies in head and neck cancer: past, present, and future
Szturz P., Vermorken J.B., 2018/12/01. Belgian Journal of Medical Oncology, 12 pp. 3-14. Peer-reviewed.
[serval:BIB_35E051ACC9B2]
 
Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.
Sonpavde G.P., Mariani L., Lo Vullo S., Raggi D., Giannatempo P., Bamias A., Crabb S.J., Bellmunt J., Yu E.Y., Niegisch G. et al., 2018/12. The Journal of urology, 200 (6) pp. 1207-1214. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4618A1755B27]
 
Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.
Necchi A., Pond G.R., Smaldone M.C., Pal S.K., Chan K., Wong Y.N., Viterbo R., Sonpavde G., Harshman L.C., Crabb S. et al., 2018/12. European urology focus, 4 (6) pp. 937-945. Peer-reviewed.
[DOI][Pmid][serval:BIB_104CA95A4385]
 
Treatment of Elderly Patients with Head and Neck Cancer.
Szturz P., Vermorken J.B., 2018/11/13. pp. 285-307 dans Critical Issues in Head and Neck Oncology: Key Concepts from the Sixth THNO Meeting. chap. 20, Vermorken JB, Budach V, Leemans CR, Machiels JP, Nicolai P, O'Sullivan B (eds.)..
[DOI][serval:BIB_E8F242D68CED]
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.
Gadgeel S., Peters S., Mok T., Shaw A.T., Kim D.W., Ou S.I., Pérol M., Wrona A., Novello S., Rosell R. et al., 2018/11/01. Annals of oncology, 29 (11) pp. 2214-2222. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_903C24CD6C23]
 
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.
Metaxas Y., Rivalland G., Mauti L.A., Klingbiel D., Kao S., Schmid S., Nowak A.K., Gautschi O., Bartnick T., Hughes B.G. et al., 2018/11. Journal of thoracic oncology, 13 (11) pp. 1784-1791. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2C36AC8D11B9]
A severe case of neuro-Sjögren's syndrome induced by pembrolizumab.
Ghosn J., Vicino A., Michielin O., Coukos G., Kuntzer T., Obeid M., 2018/10/22. Journal for immunotherapy of cancer, 6 (1) p. 110. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3E8CC11BAFBA]
 
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.
Lewin J., Soria J.C., Stathis A., Delord J.P., Peters S., Awada A., Aftimos P.G., Bekradda M., Rezai K., Zeng Z. et al., 2018/10/20. Journal of clinical oncology, 36 (30) pp. 3007-3014. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C3E1143B2AA2]
Effect of national HIV testing recommendations and local interventions on HIV testing practices in a Swiss university hospital: a retrospective analysis between 2012 and 2015.
Lazzarino T., Martenet S., Mamin R., Du Pasquier R.A., Peters S., Perreau M., Muller O., Hugli O., Cavassini M., Darling KEA, 2018/10/03. BMJ open, 8 (10) pp. e021203. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9B109EF61AEB]
 
Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Casali P.G., Bielack S., Abecassis N., Aro H.T., Bauer S., Biagini R., Bonvalot S., Boukovinas I., Bovee JVMG, Brennan B. et al., 2018/10/01. Annals of oncology, 29 (Suppl 4) pp. iv79-iv95. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_007BD2452155]
 
CN29: The use of patient reported outcome (PRO) instruments in immune checkpoint inhibitor (ICI) therapy for cancer: A systematic review
Colomer-Lahiguera S., Bryant-Lukosius D., Rietkoetter S., Martelli L., Ribi K., Orcurto A., Juergens R., Eicher M., 2018/10., 43rd ESMO Congress (ESMO) pp. viii690 dans Annals of Oncology.
[DOI][WoS][serval:BIB_E7D482C90BE4]
 
CN54: Nurse-led approaches to self-management of symptoms in routine Swiss outpatient care: A qualitative exploration
Ribi K., Bana M., Peters S., Kropf-Straub S., Näf E., Zürcher S., Eicher M., 2018/10., 43rd ESMO Congress (ESMO) pp. viii698 dans Annals of Oncology.
[DOI][WoS][serval:BIB_DA07A0CAAF6E]
 
Gastrointestinal Stromal Tumors.
Hohenberger P., Montemurro M., Raut C.P., Rutkowski P., 2018/10. Visceral medicine, 34 (5) pp. 376-379. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4FC3230376CC]
 
Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Casali P.G., Abecassis N., Aro H.T., Bauer S., Biagini R., Bielack S., Bonvalot S., Boukovinas I., Bovee JVMG, Brodowicz T. et al., 2018/10/01. Annals of oncology, 29 (Suppl 4) pp. iv68-iv78. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3D42360AD706]
 
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Planchard D., Popat S., Kerr K., Novello S., Smit E.F., Faivre-Finn C., Mok T.S., Reck M., Van Schil P.E., Hellmann M.D. et al., 2018/10/01. Annals of oncology, 29 (Suppl 4) pp. iv192-iv237. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_19D0B619B5A8]
 
Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Casali P.G., Abecassis N., Aro H.T., Bauer S., Biagini R., Bielack S., Bonvalot S., Boukovinas I., Bovee JVMG, Brodowicz T. et al., 2018/10/01. Annals of oncology, 29 (Suppl 4) pp. iv51-iv67. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F5BD62E5BD6A]
 
Training in communication of oncology clinicians: a position paper based on the third consensus meeting among European experts in 2018.
Stiefel F., Kiss A., Salmon P., Peters S., Razavi D., Cervantes A., Margulies A., Bourquin C., participants, 2018/10/01. Annals of oncology, 29 (10) pp. 2033-2036. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_430116900619]
 
Sex Differences in Efficacy and Toxicity of Systemic Treatments: An Undervalued Issue in the Era of Precision Oncology.
Özdemir B.C., Csajka C., Dotto G.P., Wagner A.D., 2018/09/10. Journal of clinical oncology, 36 (26) pp. 2680-2683. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1AE7BE4F2A08]
 
18F-FDG PET/CT pattern of Erdheim-Chester disease – a group of Czech patients
Řehák Z., Koukalová R., Vašina J., Ptáčník V., Szturz P., Karban J., Polívka J., Adam Z., 2018/09/01. Nukleární medicína, 7 (3) pp. 50-56. Peer-reviewed.
[serval:BIB_229461E6312E]
 
Acceptance of the Advanced Practice Nurse in Lung Cancer Role by Healthcare Professionals and Patients: A Qualitative Exploration.
Serena A., Dwyer A.A., Peters S., Eicher M., 2018/09. Journal of nursing scholarship, 50 (5) pp. 540-548. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A47FE1337B5D]
 
Delineating the Role of PD-1/PD-L1 Blockade in Advanced SCLC.
Zimmermann S., Peters S., 2018/09. Journal of thoracic oncology, 13 (9) pp. 1242-1244. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_523AAD462218]
 
Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland.
Sandmeier N., Rothschild S.I., Rothermundt C., Cathomas R., Schardt J., Berthold D., von Burg P., Müller B., Beyer J., Vogt D.R. et al., 2018/08. Clinical genitourinary cancer, 16 (4) pp. e711-e718. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2BC44A699A59]
 
Sarcoma of the heart: survival after surgery.
Niclauss L., Montemurro M., Kirsch M., Prêtre R., 2018/08/01. Interactive cardiovascular and thoracic surgery, 27 (2) pp. 198-201. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8CD8711BDE3F]
 
Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group.
Cristina V., Mahachie J., Mauer M., Buclin T., Van Cutsem E., Roth A., Wagner A.D., 2018/07/01. JAMA oncology, 4 (7) pp. 1003-1006. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_13A355872A91]
 
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial.
Wirsching H.G., Tabatabai G., Roelcke U., Hottinger A.F., Jörger F., Schmid A., Plasswilm L., Schrimpf D., Mancao C., Capper D. et al., 2018/06/01. Annals of oncology, 29 (6) pp. 1423-1430. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_385659ABD730]
 
Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08).
Ruhstaller T., Thuss-Patience P., Hayoz S., Schacher S., Knorrenschild J.R., Schnider A., Plasswilm L., Budach W., Eisterer W., Hawle H. et al., 2018/06/01. Annals of oncology, 29 (6) pp. 1386-1393. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_187C909027A6]
 
Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
Peters S., Zimmermann S., 2018/05/28. Current treatment options in oncology, 19 (7) p. 37. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5AE72E5CA1C1]
 
Immune Checkpoint Inhibitors in the Management of Lung Cancer.
Zimmermann S., Peters S., Owinokoko T., Gadgeel S.M., 2018/05/23. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 38 pp. 682-695. Peer-reviewed.
[DOI][Pmid][serval:BIB_07DB0A3C900D]
 
Efficacy and safety of the CDK4/6 inhibitor palbociclib during different lines of treatment in patients with advanced stage endocrine sensitive/HER2 negative breast cancer.
Zurcher Jean-Philippe, Aedo Veronica, Stravodimou Athina, Sarivalasis Apostolos, Zaman Khalil, 2018/05/20. Journal of Clinical Oncology, 36 (15_suppl) pp. e13052-e13052.
[DOI][WoS][serval:BIB_899C43F0DBF7]
 
De vrais espoirs et de sérieuses préoccupations
Peters S., Dietrich P.Y., Aapro M., 2018/05/16. Revue medicale suisse, 14 (607) pp. 1011-1012. Peer-reviewed.
[Pmid][serval:BIB_950C09416787]
La biopsie liquide, une nouvelle opportunité pour l’oncologie personnalisée [Liquid biopsy, a new opportunity for personalized oncology]
Astaras C., Dolcan A., Bisig B., Zaman K., 2018/05/16. Revue medicale suisse, 14 (607) pp. 1028-1032. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A01EBF6F6786]
 
Le cancer séreux de haut gradede l’ovaire en 2018 : avancéeset controverses [High grade serous ovarian cancer 2018 : advances and controversies]
Mederos N., Wolfer A., Mathevet P., Zaher M., Sarivalasis A., 2018/05/16. Revue medicale suisse, 14 (607) pp. 1037-1041. Peer-reviewed.
[Pmid][serval:BIB_BC5B14F6A299]
 
Genomic Features of Response to Combination Immunotherapy in Lung Cancer.
Früh M., Peters S., 2018/05/14. Cancer cell, 33 (5) pp. 791-793. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FD1D595C2E3A]
Porcine pulmonary valve decellularization with NaOH-based vs detergent process: preliminary in vitro and in vivo assessments.
van Steenberghe M., Schubert T., Gerelli S., Bouzin C., Guiot Y., Xhema D., Bollen X., Abdelhamid K., Gianello P., 2018/04/25. Journal of cardiothoracic surgery, 13 (1) p. 34. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B0E7D88FA7B4]
 
EML4-ALK Variant Affects ALK Resistance Mutations.
Früh M., Peters S., 2018/04/20. Journal of clinical oncology, 36 (12) pp. 1257-1259. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D1A4BC1F7EAB]
 
Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Cardoso E., Mercier T., Wagner A.D., Homicsko K., Michielin O., Ellefsen-Lavoie K., Cagnon L., Diezi M., Buclin T., Widmer N. et al., 2018/04/15. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1083 pp. 124-136. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E8B0234B5672]
 
138PD_PR Patient-reported outcomes (PROs) in ALEX: A phase III study of alectinib (ALEC) vs crizotinib (CRIZ) in non-small-cell lung cancer (NSCLC)
Perol M., Peters S., Pavlakis N., Levchenko E., Platania M., Oliveira J., Novello S., Karagiannis T., Zeaiter A., Dziadziuszko R., 2018/04. Journal of Thoracic Oncology, 13 (4) pp. S80-S81.
[DOI][serval:BIB_92F7FE327F60]
 
Immune-related adverse events of immune checkpoint inhibitors and the impact of sex-what we know and what we need to learn.
Özdemir B.C., Coukos G., Wagner A.D., 2018/04/01. Annals of oncology, 29 (4) p. 1067. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_888420F74085]
 
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Taphoorn MJB, Dirven L., Kanner A.A., Lavy-Shahaf G., Weinberg U., Taillibert S., Toms S.A., Honnorat J., Chen T.C., Sroubek J. et al., 2018/04/01. JAMA oncology, 4 (4) pp. 495-504. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DEAA0BF555E3]
 
Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07).
Montemurro M., Cioffi A., Dômont J., Rutkowski P., Roth A.D., von Moos R., Inauen R., Toulmonde M., Burkhard R.O., Knuesli C. et al., 2018/04/01. Cancer, 124 (7) pp. 1449-1454. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_423A807460D5]
 
Sexualité après un cancer du sein: un sujet non tabou [Sexuality after breast cancer is not a taboo]
Cairo Notari S., Fornage S., Panes-Ruedin B., Zaman K., 2018/03/14. Revue medicale suisse, 14 (598) pp. 563-565. Peer-reviewed.
[Pmid][serval:BIB_BF3965CC00D9]
Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.
Viala M., Vinches M., Alexandre M., Mollevi C., Durigova A., Hayaoui N., Homicsko K., Cuenant A., Gongora C., Gianni L. et al., 2018/03/06. British journal of cancer, 118 (5) pp. 679-697. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B98F6A7521FE]
 
Dexrazoxane prevents skin necrosis in non-target embolization of falciform artery during transcatheter arterial chemoembolization (TACE).
Stalder G., Deplanque G., Shabafrouz K., Orcurto A., Bize P., Duran R., Denys A., 2018/03. Diagnostic and interventional imaging, 99 (3) pp. 179-180. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_38FC0E37F29B]
Natalizumab may control immune checkpoint inhibitor-induced limbic encephalitis.
Hottinger A.F., de Micheli R., Guido V., Karampera A., Hagmann P., Du Pasquier R., 2018/03. Neurology, 5 (2) pp. e439. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_936AFB128A84]
 
Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly.
Costantini A., Grynovska M., Lucibello F., Moisés J., Pagès F., Tsao M.S., Shepherd F.A., Bouchaab H., Garassino M., Aerts JGJV et al., 2018/02. The European respiratory journal, 51 (2) pp. NA. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_186255E114C9]
 
Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management.
Astaras C., de Micheli R., Moura B., Hundsberger T., Hottinger A.F., 2018/02/01. Current neurology and neuroscience reports, 18 (1) p. 3. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0037F78B4822]
A Dual-Color Bioluminescence Reporter Mouse for Simultaneous in vivo Imaging of T Cell Localization and Function.
Kleinovink J.W., Mezzanotte L., Zambito G., Fransen M.F., Cruz L.J., Verbeek J.S., Chan A., Ossendorp F., Löwik C., 2018. Frontiers in immunology, 9 p. 3097. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A6143E0B1670]
 
Current Opinion and Knowledge on Peritoneal Carcinomatosis: A Survey among a Swiss Oncology Network.
Grass F., Martin D., Montemurro M., Mathevet P., Wolfer A., Coukos G., Demartines N., Hübner M., 2018. Chemotherapy, 63 (3) pp. 143-147. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4174AA4D6600]
Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity.
Tsoutsou P.G., Zaman K., Martin Lluesma S., Cagnon L., Kandalaft L., Vozenin M.C., 2018. Frontiers in oncology, 8 p. 609. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3F237867AE06]
Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey.
Banerjee S., Dafni U., Allen T., Arnold D., Curigliano G., Garralda E., Garassino M.C., Haanen J., Hofstädter-Thalmann E., Robert C. et al., 2018. ESMO open, 3 (6) pp. e000422. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A210CE25B3B9]
Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program.
Balmelli C., Railic N., Siano M., Feuerlein K., Cathomas R., Cristina V., Güthner C., Zimmermann S., Weidner S., Pless M. et al., 2018. Journal of Cancer, 9 (2) pp. 250-255. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_13DAD73D00CC]
PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
Peters S., Kerr K.M., Stahel R., 2018/01. Cancer treatment reviews, 62 pp. 39-49. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AA60ECC5901D]
 
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project.
Kerr K.M., Dafni U., Schulze K., Thunnissen E., Bubendorf L., Hager H., Finn S., Biernat W., Vliegen L., Losa J.H. et al., 2018/01/01. Annals of oncology, 29 (1) pp. 200-208. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_39FAD748912D]
Report on the status of women occupying leadership roles in oncology.
Hofstädter-Thalmann E., Dafni U., Allen T., Arnold D., Banerjee S., Curigliano G., Garralda E., Garassino M.C., Haanen J., Robert C. et al., 2018. ESMO open, 3 (6) pp. e000423. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_55ECD14DC6C8]
Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.
Voruz S., Cairoli A., Naveiras O., de Leval L., Missiaglia E., Homicsko K., Michielin O., Blum S., 2018/01. Haematologica, 103 (1) pp. e39-e41. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_12A8F7D8B626]
 
Testicular Estrogen-Secreting Leydig Cell Tumor in 18F-FDG PET/CT: An Incidental Detection in a Patient Treated by Chemotherapy for Hodgkin Lymphoma.
Van Der Gucht A., Maged Z., Burruni R., Barras J.L., Schaefer N., 2018/01. Clinical nuclear medicine, 43 (1) pp. 41-43. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_745DDBA3FD88]
2017
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Stupp R., Taillibert S., Kanner A., Read W., Steinberg D.M., Lhermitte B., Toms S., Idbaih A., Ahluwalia M.S., Fink K. et al., 2017/12/19. JAMA, 318 (23) pp. 2306-2316. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_868908B10151]
 
Cancer immunotherapy full speed ahead.
Melero I., Navarro B., Teijeira A., Coukos G., 2017/12/01. Annals of oncology, 28 (suppl_12) pp. xii1-xii2. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DA57E8E33449]
 
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors.
Stathis A., Hess D., von Moos R., Homicsko K., Griguolo G., Joerger M., Mark M., Ackermann C.J., Allegrini S., Catapano C.V. et al., 2017/12. Investigational new drugs, 35 (6) pp. 766-772. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2BBC028AA0E8]
 
Questions about the formulation of erythropoietin mouthwash for the prevention of oral mucositis.
Fleury M., Shabafrouz K., Deplanque G., 2017/12. Hematological oncology, 35 (4) p. 931. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B8729B1EE2E7]
 
Ablation du cancer primaire dans les néoplasies urologiques oligométastatiques : évidence ou vœux pieux ? [Local treatment in oligometastatic urological malignancies : evidence of wishful thinking ?]
Valerio M., Cerantola Y., Lucca I., Berthold D., Jichlinski P., 2017/11/29. Revue medicale suisse, 13 (585) pp. 2083-2086. Peer-reviewed.
[Pmid][serval:BIB_3B730D56DD60]
Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer.
Rizvi N.A., Peters S., 2017/11/16. The New England journal of medicine, 377 (20) pp. 1986-1988. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_209668DAE913]
 
Nouvelle classification OMS 2016 des gliomes : quels changements ? [Revised WHO classification 2016 of gliomas : what's new ?]
Brouland J.P., Hottinger A.F., 2017/10/18. Revue medicale suisse, 13 (579) pp. 1805-1809. Peer-reviewed.
[Pmid][serval:BIB_A56796E81114]
 
Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG.
Kataoka K., Kinoshita T., Moehler M., Mauer M., Shitara K., Wagner A.D., Schrauwen S., Yoshikawa T., Roviello F., Tokunaga M. et al., 2017/09. Gastric cancer, 20 (5) pp. 904-912. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_989189C4915D]
Iterative Reconstructions in Reduced-Dose CT: Which Type Ensures Diagnostic Image Quality in Young Oncology Patients?
Pauchard B., Higashigaito K., Lamri-Senouci A., Knebel J.F., Berthold D., Verdun F.R., Alkadhi H., Schmidt S., 2017/09. Academic radiology, 24 (9) pp. 1114-1124. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D9286BF48739]
 
Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project.
Bubendorf L., Dafni U., Schöbel M., Finn S.P., Tischler V., Sejda A., Marchetti A., Thunnissen E., Verbeken E.K., Warth A. et al., 2017/09. Lung cancer, 111 pp. 143-149. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_09A7AE9EE6F6]
Chemotherapy for advanced gastric cancer.
Wagner A.D., Syn N.L., Moehler M., Grothe W., Yong W.P., Tai B.C., Ho J., Unverzagt S., 2017/08/29. The Cochrane database of systematic reviews, 8 pp. CD004064. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8819477F408B]
 
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
Peters S., Gettinger S., Johnson M.L., Jänne P.A., Garassino M.C., Christoph D., Toh C.K., Rizvi N.A., Chaft J.E., Carcereny Costa E. et al., 2017/08/20. Journal of clinical oncology, 35 (24) pp. 2781-2789. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E3A57103263A]
 
Feasibility of advanced practice nursing in lung cancer consultations during early treatment: A phase II study.
Serena A., Dwyer A., Peters S., Eicher M., 2017/08. European journal of oncology nursing, 29 pp. 106-114. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DE0FAF413030]
Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.
Mangana J., Cheng P.F., Kaufmann C., Amann V.C., Frauchiger A.L., Stögner V., Held U., von Moos R., Michielin O., Braun R.P. et al., 2017/08. Melanoma research, 27 (4) pp. 358-368. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_15F2678EE65F]
 
Scientific Advances in Thoracic Oncology 2016.
Soo R.A., Stone ECA, Cummings K.M., Jett J.R., Field J.K., Groen HJM, Mulshine J.L., Yatabe Y., Bubendorf L., Dacic S. et al., 2017/08. Journal of thoracic oncology, 12 (8) pp. 1183-1209. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9B3F2A576586]
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
James N.D., de Bono J.S., Spears M.R., Clarke N.W., Mason M.D., Dearnaley D.P., Ritchie AWS, Amos C.L., Gilson C., Jones R.J. et al., 2017/07/27. The New England journal of medicine, 377 (4) pp. 338-351. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CF2E19F79ACD]
mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.
Zabala-Letona A., Arruabarrena-Aristorena A., Martín-Martín N., Fernandez-Ruiz S., Sutherland J.D., Clasquin M., Tomas-Cortazar J., Jimenez J., Torres I., Quang P. et al., 2017/07/06. Nature, 547 (7661) pp. 109-113. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A2A21769118A]
 
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours.
Le Rhun E., Weller M., Brandsma D., Van den Bent M., de Azambuja E., Henriksson R., Boulanger T., Peters S., Watts C., Wick W. et al., 2017/07/01. Annals of oncology, 28 (suppl_4) pp. iv84-iv99. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_061F0A1BEC72]
 
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Postmus P.E., Kerr K.M., Oudkerk M., Senan S., Waller D.A., Vansteenkiste J., Escriu C., Peters S., ESMO Guidelines Committee, 2017/07/01. Annals of oncology, 28 (suppl_4) pp. iv1-iv21. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A0D5760F710A]
 
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Haanen JBAG, Carbonnel F., Robert C., Kerr K.M., Peters S., Larkin J., Jordan K., ESMO Guidelines Committee, 2017/07/01. Annals of oncology, 28 (Suppl_4) pp. iv119-iv142. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_80754A023E6E]
 
Extra central nervous system metastases from glioblastoma: a new possible trigger event?
Simonetti G., Silvani A., Fariselli L., Hottinger A.F., Pesce G.A., Prada F., Gaviani P., 2017/06/24. Neurological sciences, 38 (10) pp. 1873-1875. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7F947922E674]
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
Carbone D.P., Reck M., Paz-Ares L., Creelan B., Horn L., Steins M., Felip E., van den Heuvel M.M., Ciuleanu T.E., Badin F. et al., 2017/06/22. The New England journal of medicine, 376 (25) pp. 2415-2426. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5A4A2E2F4748]
 
Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program.
Papazoglou D., Wannesson L., Berthold D., Cathomas R., Gillessen S., Rothermundt C., Hasler L., Winterhalder R., Barth A., Mingrone W. et al., 2017/06. Clinical genitourinary cancer, 15 (3) pp. e315-e323. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_80EDD64A446F]
 
Metastatic soft tissue sarcoma: current treatment landscape and future perspectives.
Skafida E., Kokkali S., Nikolaou M., Digklia A., 2017/06. Expert review of anticancer therapy, 17 (6) pp. 537-543. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_73DC47A54E2B]
 
Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC).
Stinchcombe Tom, Stahel Rolf A., Bubendorf Lukas, Bonomi Philip, Villegas Augusto E., Kowalski Dariusz, Baik Christina S., Isla Dolores, De Castro Javier, Garrido Lopez Pilar et al., 2017/05/20. Journal of Clinical Oncology, 35 (15_suppl) pp. 8509-8509.
[DOI][WoS][serval:BIB_5CB69D973D69]
 
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels.
Casali P.G., Zalcberg J., Le Cesne A., Reichardt P., Blay J.Y., Lindner L.H., Judson I.R., Schöffski P., Leyvraz S., Italiano A. et al., 2017/05/20. Journal of clinical oncology, 35 (15) pp. 1713-1720. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7389B430762C]
 
Cancer du sein de stade précoce : la désescalade thérapeutique sélective [Selective therapeutic de-escalation in early stage breast cancer]
Liapi A., Sarivalasis A., Jeanneret Sozzi W., Lelièvre L., Zaman K., 2017/05/17. Revue medicale suisse, 13 (563) pp. 1035-1038. Peer-reviewed.
[Pmid][serval:BIB_24E1E827BE9A]
 
Cancer du sein de stade précoce : la désescalade thérapeutique sélective [Selective therapeutic de-escalation in early stage breast cancer]
Liapi A., Sarivalasis A., Jeanneret Sozzi W., Lelièvre L., Zaman K., 2017/05/17. Revue medicale suisse, 13 (563) pp. 1035-1038. Peer-reviewed.
[Pmid][serval:BIB_7A29F888A008]
 
Cancers de la sphère ORL : l’immunothérapie donne de la voix ! [Head and neck cancer : promising results of immunotherapy]
Sivade A., Bensaid D., Monnier Y., Shabafrouz K., Bouchaab H., Cristina V., 2017/05/17. Revue medicale suisse, 13 (563) pp. 1029-1031. Peer-reviewed.
[Pmid][serval:BIB_FFCBF161F44F]
 
Carcinome hépatocellulaire avancé : nouveautés de la thérapie systémique et place du traitement local ? [Treatment of advanced hepatocellular carcinoma : Novel agents and role of local therapy]
Parisod L., Duran R., Denys A., Digklia A., 2017/05/17. Revue medicale suisse, 13 (563) pp. 1032-1034. Peer-reviewed.
[Pmid][serval:BIB_B80B0D598281]
 
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
Rosell R., Dafni U., Felip E., Curioni-Fontecedro A., Gautschi O., Peters S., Massutí B., Palmero R., Aix S.P., Carcereny E. et al., 2017/05. The Lancet. Respiratory medicine, 5 (5) pp. 435-444. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D6307005064D]
 
An exploratory study on the use of traditional, complementary and alternative medicines (TCAM) by cancer patients
Fleury Mapi, peters solange, beck maja, sadeghipour farshid, 2017/04. dans Abstracts of the MASCC/ISOO 2017 Annual Meeting. Peer-reviewed.
[DOI][serval:BIB_CD9843AB7B3E]
 
Abstract P6-09-52: Prognostic factors in breast cancer (BC) associated with the development of brain metastases (BM): A retrospective study of 726 pts
Santa Cruz O, Tsoutsou P, Anchisi S, Khanfir K, Negretti L, Girardet C, Ozsoy O, Ozsahin M, 2017/02/15., San Antonio Breast Cancer Symposium pp. P6-09-52-P6-09-52 dans Cancer Research, American Association for Cancer Research (AACR).
[DOI][WoS][serval:BIB_14F6EEDDA1DE]
 
Pharmacien : un regard complémentaire pour la sécurité du patient
Fleury Mapi, 2017/02/14. Soins en Oncologie, 1 (1) pp. 19-20.
[serval:BIB_F92D793ADB3B]
 
Comparison of three or fewer high-dose chemotherapy cycles as salvage treatment in germ cell tumors in first relapse.
Gössi F., Spahn M., Zweifel M., Panagiotis S., Mischo A., Stenner F., Hess U., Berthold D., Bargetzi M., Schardt J. et al., 2017/02. Bone marrow transplantation, 52 (2) pp. 334-336. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6A7B320CEE17]
 
Current Trends in Thoracic Radio-oncology
Matzinger O, Peters S, 2017/02/01. Schweizer Krebsbulletin, Nr 2/2017.
[serval:BIB_35E08FB97BA2]
 
Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99.
Pagani O., Klingbiel D., Ruhstaller T., Nolè F., Eppenberger S., Oehlschlegel C., Bernhard J., Brauchli P., Hess D., Mamot C. et al., 2017/02/01. Annals of oncology, 28 (2) pp. 305-312. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FE5A9B2D8723]
 
ETOP and its role in lung cancer research in Europe
Roschitzki-Voser H, Maibach R, Stahel R, Peters S, 2017/02/01. Schweizer Krebsbulletin, Nr 2/2017.
[serval:BIB_3CC04BA10483]
 
Feasibility of advanced practice nurse in lung cancer consultations during early treatment: a phase II study
Serena A., Dwyer A., Peters S., Eicher M., 2017/02. European Journal of Cancer, 72 pp. S160.
[DOI][serval:BIB_D1DE879B1916]
 
Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
Necchi A., Sonpavde G., Lo Vullo S., Giardiello D., Bamias A., Crabb S.J., Harshman L.C., Bellmunt J., De Giorgi U., Sternberg C.N. et al., 2017/02. European urology, 71 (2) pp. 281-289. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7F8625159D29]
 
Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer.
Evans TRJ, Van Cutsem E., Moore M.J., Bazin I.S., Rosemurgy A., Bodoky G., Deplanque G., Harrison M., Melichar B., Pezet D. et al., 2017/02/01. Annals of oncology, 28 (2) pp. 354-361. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_50D2E9A71929]
 
Un regard critique sur l’innovation
Peters S, 2017/02/01. Schwerpunktthema "Lungenkrebs" Schweizer Krebsbulletin, Nr 2/2017..
[serval:BIB_8E912D3F7800]
 
Activity of afatinib in heavily pretreated patients with HER2 mutation-positive advanced NSCLC: findings from a global named patient use program,
Peters S., Curioni-Fontecedro A., Nechushtan H., Shih J.-Y., Liao W.-Y., Gautschi O., Spataro V., Unk M., Yang JCH, Lorence RM et al., 2017. Annals of Oncology, 28 (5) pp. v484-v485.
[DOI][serval:BIB_0FB97EBE99F9]
 
ESMO Handbook of Immuno-Oncology
Peters Solange, Zimmermann Stefan, 2017/01/01., ESMO.
[serval:BIB_B92B3C64442C]
 
Establishing a formal sarcoma center for children and adults at the Lausanne University Hospital
Bosisio Francesca, Matter Maurice, Fortin Aurélie, CHUV Multidisciplinary Sarcoma Team, 2017. Swiss Knife 3 pp. 16-19. Peer-reviewed.
[serval:BIB_B13928EA1DBE]
 
Immunotherapy and Targeted Therapies in the Treatment of Non-small Cell Lung Cancer
Nguyen-Ngoc Tu, Reck Martin, Tan Daniel SW, Peters Solange, 2017. European Oncology & Haematology, 13 (01) p. 35.
[DOI][serval:BIB_F210C40D2190]
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy
Manegold Christian, Adjei Alex, Bussolino Federico, Cappuzzo Federico, Crino Lucio, Dziadziuszko Rafal, Ettinger David, Fennell Dean, Kerr Keith, Le Chevalier Thierry et al., 2017/01. ESMO Open, 1 (6) pp. e000118. Peer-reviewed.
[URN][DOI][WoS][serval:BIB_D93B50365865]
 
On-the-Fly QM/MM Docking with Attracting Cavities.
Chaskar P., Zoete V., Röhrig U.F., 2017. Journal of Chemical Information and Modeling, 57 (1) pp. 73-84. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_47CBD7F371A0]
Patient and doctor perspectives on HIV screening in the emergency department: A prospective cross-sectional study.
De Rossi N., Dattner N., Cavassini M., Peters S., Hugli O., Darling KEA, 2017. PloS one, 12 (7) pp. e0180389. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BA94D80A49E2]
 
Side Effects of Medical Cancer Therapy, 2nd Edition
Dicato Mario (eds.)Peters Solange, 2017/01/01., Springer Verlag .
[serval:BIB_7D3388D607F9]
 
The Binding Mode of N-Hydroxyamidines to Indoleamine 2,3-Dioxygenase 1 (IDO1).
Röhrig U.F., Zoete V., Michielin O., 2017. Biochemistry, 56 (33) pp. 4323-4325. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B02CF9601B42]
 
The case of an extensive primary extramammary Paget's disease diagnosis and treatment
Sarivalasis Apostolos, Triboulet Cécile, Anchisi Sandro, 2017. International Journal of Case Reports and Images, 8 (01) p. 46.
[DOI][serval:BIB_C9F2C6F7196D]
2016
 
Centre des sarcomes : un nouvel outil pour améliorer la prise en charge du patient et soutenir la recherche [Sarcoma centres : a necessary tool in the management of patients and for research.]
Cherix S., Vauclair F., Morattel B., Vautrin M., Matter M., Montemurro M., Digklia A., Letovanec I., Omoumi P., Saucy F. et al., 2016/12/14. Revue medicale suisse, 12 (543) pp. 2172-2176. Peer-reviewed.
[Pmid][serval:BIB_B4139C33D819]
 
Confusion between Two Amphotericin B Formulations Leading to a Paediatric Rehospitalisation
Fleury Mapi, Fonzo-Christe Caroline, Normand Charline, Bonnabry Pascal, 2016/12. Drug Safety - Case Reports, 3 (1). Peer-reviewed.
[DOI][Pmid][serval:BIB_59BB836EFA18]
Current management of low-grade gliomas.
Hottinger A.F., Hegi M.E., Baumert B.G., 2016/12. Current opinion in neurology, 29 (6) pp. 782-788. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AA45A63A4CB1]
 
Neurologic complications of immune checkpoint inhibitors.
Hottinger A.F., 2016/12. Current opinion in neurology, 29 (6) pp. 806-812. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F475869CA02A]
 
Neurooncology: a Swiss army knife specialty.
Hottinger A.F., 2016/12. Current opinion in neurology, 29 (6) p. 781. Peer-reviewed.
[DOI][Pmid][serval:BIB_D40536BC3C52]
Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors.
Hofheinz R.D., Deplanque G., Komatsu Y., Kobayashi Y., Ocvirk J., Racca P., Guenther S., Zhang J., Lacouture M.E., Jatoi A., 2016/12. The oncologist, 21 (12) pp. 1483-1491. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E427F6ADBB5D]
 
Médicaments usuels en médecine de premier recours et cancer de la prostate : quelle relation ? [Common medications and prostate cancer : what is the association ?]
Rakauskas A., Grilo N., M'Baya O., Jichlinski P., Valerio M., Berthold D., 2016/11/30. Revue medicale suisse, 12 (541) pp. 2068-2071. Peer-reviewed.
[Pmid][serval:BIB_A37D39541A4B]
 
Nodules pulmonaires subsolides [Subsolid pulmonary nodules]
Keller D., Beigelman-Aubry C., Letovanec I., Bouchaab H., Gonzalez M., Lovis A., Nicod L.P., Lazor R., 2016/11/16. Revue medicale suisse, 12 (539) pp. 1976-1982. Peer-reviewed.
[Pmid][serval:BIB_D4E01C05495D]
 
ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD-L1-Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results: Topic: Medical Oncology.
Peters Solange (eds.), 2016/11., 11 11S.
[DOI][Pmid][serval:BIB_10824FA7CB0E]
 
PS01.58: A Phase 3 Trial of Nivolumab, Nivolumab Plus Ipilimumab, or Placebo Maintenance for Extensive-Stage SCLC After First-Line Chemotherapy
Owonikoko T., Ready N., Postmus P., Reck M., Peters S., Pieters A., Selvaggi G., Fairchild J., Govindan R., 2016/11. pp. S306-S307 dans Journal of Thoracic Oncology. Peer-reviewed, Elsevier BV.
[DOI][Pmid][serval:BIB_686D1C598803]
 
Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial.
Früh M., Ris H.B., Xyrafas A., Peters S., Mirimanoff R.O., Gautschi O., Pless M., Stupp R., 2016/10. Annals of oncology, 27 (10) pp. 1971-1973. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B17A250595A6]
Tumor treating fields: a novel treatment modality and its use in brain tumors.
Hottinger A.F., Pacheco P., Stupp R., 2016/10. Neuro-oncology, 18 (10) pp. 1338-1349. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1E5E2F0B2497]
 
Hormonothérapie dans le cancer du sein invasif, update 2016 [Hormone therapy in invasive breast cancer : update 2016]
Zurcher J.P., Stravodimou A., Zaman K., 2016/09/21. Revue medicale suisse, 12 (531) pp. 1580-1583. Peer-reviewed.
[Pmid][serval:BIB_50C445402734]
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
Dittrich Christian, Kosty Michael, Jezdic Svetlana, Pyle Doug, Berardi Rossana, Bergh Jonas, El-Saghir Nagi, Lotz Jean-Pierre, Österlund Pia, Pavlidis Nicholas et al., 2016/09. ESMO Open, 1 (5) pp. e000097. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_FECB702281DB]
Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma.
Hoeller C., Michielin O., Ascierto P.A., Szabo Z., Blank C.U., 2016/09. Cancer immunology, immunotherapy : CII, 65 (9) pp. 1015-1034. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_8EBC6CB579E4]
 
SwissSimilarity: A Web Tool for Low to Ultra High Throughput Ligand-Based Virtual Screening.
Zoete V., Daina A., Bovigny C., Michielin O., 2016/08/22. Journal of chemical information and modeling, 56 (8) pp. 1399-1404. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C596B8B7E91E]
ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016.
Dittrich C., Kosty M., Jezdic S., Pyle D., Berardi R., Bergh J., El Saghir N., Lotz J.P., Österlund P., Pavlidis N. et al., 2016/08. Annals of oncology, 27 (8) pp. 1378-1381. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_90E7C2FE8093]
Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.
Pivot X., Marmé F., Koenigsberg R., Guo M., Berrak E., Wolfer A., 2016/08. Annals of oncology, 27 (8) pp. 1525-1531. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_43D394D01C9D]
 
Hypofractionated radiotherapy in pancreatic cancer: Lessons from the past in the era of stereotactic body radiation therapy.
De Bari B., Porta L., Mazzola R., Alongi F., Wagner A.D., Schäfer M., Bourhis J., Ozsahin M., 2016/07. Critical reviews in oncology/hematology, 103 pp. 49-61. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_EE057E94F72E]
Traitement curatif du cancer de l'oesophage: consensus multidisciplinaire multicentrique [Curative treatment for esophageal cancer: results of a multidisciplinary consensus]
Allemann P., Mantziari S., Wagner D., Digklia A., Ozsahin E., De Bari B., Dorta G., Godat S., Montserrat F., Sempoux C. et al., 2016/06/15. Revue medicale suisse, 12 (523) pp. 1165-1169. Peer-reviewed.
[URN][Pmid][serval:BIB_58E6531A0AFA]
 
Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial.
Deplanque G., Gervais R., Vergnenegre A., Falchero L., Souquet P.J., Chavaillon J.M., Taviot B., Fraboulet G., Saal H., Robert C. et al., 2016/06. Journal of the American Academy of Dermatology, 74 (6) pp. 1077-1085. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_052A1F59D618]
 
Efficacy and safety of helical tomotherapy with daily image guidance in anal canal cancer patients.
De Bari B., Jumeau R., Bouchaab H., Vallet V., Matzinger O., Troussier I., Mirimanoff R.O., Wagner A.D., Hanhloser D., Bourhis J. et al., 2016/06. Acta oncologica (Stockholm, Sweden), 55 (6) pp. 767-773. Peer-reviewed.
[DOI][Pmid][serval:BIB_BBF294B0BDC2]
 
Carcinome rénal métastatique, retour vers le futur... [Metastatic renal cell carcinoma, back to the future]
Martins F., Berthold D., 2016/05/18. Revue medicale suisse, 12 (519) pp. 994-998. Peer-reviewed.
[Pmid][serval:BIB_51ABC794800F]
 
Scientific Advances in Lung Cancer 2015.
Tsao A.S., Scagliotti G.V., Bunn P.A., Carbone D.P., Warren G.W., Bai C., de Koning H.J., Yousaf-Khan A.U., McWilliams A., Tsao M.S. et al., 2016/05. Journal of thoracic oncology, 11 (5) pp. 613-638. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_02E8A7A685FB]
 
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29).
Koeberle D., Dufour J.F., Demeter G., Li Q., Ribi K., Samaras P., Saletti P., Roth A.D., Horber D., Buehlmann M. et al., 2016/05. Annals of oncology, 27 (5) pp. 856-861. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_22900D1DA607]
 
Weekly Multi-agent Chemotherapy (CMF-b) for Advanced Non-melanoma Skin Cancer.
Espeli V., Ruegg E., Hottinger A.F., Modarressi A., Dietrich P.Y., 2016/05. Anticancer research, 36 (5) pp. 2359-2364. Peer-reviewed.
[Pmid][serval:BIB_FEB5E0F16A8A]
 
Prise en charge des tumeurs cérébrales primaires: une approche multidisciplinaire [Multidisciplinar approach to the management of gliomas]
Moura B., Migliorini D., Bourhis J., Daniel R., Levivier M., Hottinger A.F., 2016/04/27. Revue medicale suisse, 12 (516) pp. 821-825.
[Pmid][serval:BIB_195E897B3E1C]
Initial Staging of Locally Advanced Rectal Cancer and Regional Lymph Nodes: Comparison of Diffusion-Weighted MRI With 18F-FDG-PET/CT.
Cerny M., Dunet V., Prior J.O., Hahnloser D., Wagner A.D., Meuli R.A., Schmidt S., 2016/04. Clinical nuclear medicine, 41 (4) pp. 289-295. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D1C7BBCC2191]
 
Recent advances in the management of atypical meningiomas.
Messerer M., Richoz B., Cossu G., Dhermain F., Hottinger A.F., Parker F., Levivier M., Daniel R.T., 2016/04. Neuro-Chirurgie, 62 (4) pp. 213-222. Peer-reviewed.
[DOI][Pmid][serval:BIB_FD65BBDB7034]
 
The French initiative paves the way: routine molecular profiling of advanced non-small-cell lung cancer fights inequalities in access to molecular targeted therapy and improves patient outcome
Peters Solange, Zimmermann Stefan, 2016/04. Translational Cancer Research, 5 (2) pp. 124-126.
[DOI][WoS][serval:BIB_687AFD8FE984]
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
James N.D., Sydes M.R., Clarke N.W., Mason M.D., Dearnaley D.P., Spears M.R., Ritchie A.W., Parker C.C., Russell J.M., Attard G. et al., 2016/03/19. Lancet (London, England), 387 (10024) pp. 1163-1177. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_2BB6C537D055]
Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis.
Dunet V., Pomoni A., Hottinger A., Nicod-Lalonde M., Prior J.O., 2016/03. Neuro-oncology, 18 (3) pp. 426-434. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C1621CCB076D]
 
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Mazières J., Barlesi F., Filleron T., Besse B., Monnet I., Beau-Faller M., Peters S., Dansin E., Früh M., Pless M. et al., 2016/02. Annals of oncology : official journal of the European Society for Medical Oncology, 27 (2) pp. 281-286. Peer-reviewed.
[DOI][Pmid][serval:BIB_663787DE1313]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University